BioAge Labs宣布QUEL-DME研究完成首位受试者给药——新型口服NLRP3抑制剂BGE-102针对糖尿病性黄斑水肿的Ⅱ期临床试验正式启动

美股速递
Sep 08

BioAge Labs日前宣布,其在研新型口服NLRP3抑制剂BGE-102的Ⅱ期临床试验QUEL-DME已顺利完成首位受试者给药。该试验旨在评估这一创新候选药物在糖尿病性黄斑水肿患者中的疗效与安全性。

此次里程碑式的进展,标志着BioAge Labs在推进口服小分子抗炎疗法治疗眼科疾病方面迈出了关键一步。糖尿病性黄斑水肿是糖尿病视网膜病变中导致视力损害的重要原因,长期以来一直是眼科治疗领域亟待满足的临床需求。

BGE-102作为一种口服NLRP3抑制剂,其作用机制聚焦于抑制炎症小体的异常激活,从源头上阻断炎症级联反应。相较于传统疗法,这一新型策略有望提供更为便捷的给药方式,同时为难以从现有抗VEGF治疗中充分获益的患者群体带来新的治疗选择。

QUEL-DME研究的启动与首例受试者的成功入组,不仅验证了BioAge Labs在药物研发管线推进上的执行力,也为其在代谢相关并发症及慢性炎症性疾病领域的战略布局增添了新的注脚。

展望后续,随着更多临床数据的陆续读出,BGE-102在糖尿病性黄斑水肿乃至其他NLRP3介导疾病中的治疗潜力将进一步得到清晰呈现,其临床进展值得市场与学术界的持续关注。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10